Tozinameran is an RNA vaccine composed of nucleoside-modified mRNA encoding a mutated form of the spike protein of SARS-CoV-2. Trials began in April 2020; by November, the vaccine had been tested on more than 40,000 people. Pfizer indicated in November 2020, that 50 million doses could be available globally by the end of 2020, with about 1.3billion doses in 2021.
About Tozinameran in brief
Tozinameran is an RNA vaccine composed of nucleoside-modified mRNA encoding a mutated form of the spike protein of SARS-CoV-2. Trials began in April 2020; by November, the vaccine had been tested on more than 40,000 people. Pfizer indicated in November 2020, that 50 million doses could be available globally by the end of 2020, with about 1.3 billion doses in 2021. The vaccination requires two doses given three weeks apart. Its ability to prevent severe infection in children, pregnant women, or immunocompromised people is unknown, as is the duration of the immune effect it confers. As of December 2020, reports of serious side effects, such as allergic reactions, have been very rare, and no long-term complications have been reported. The most common side effects include mild to moderate pain at the injection site, fatigue, and headache. By 20 December over half a million people in Britain had received the vaccine as part of its national vaccination programme. In September 2020, the German government granted BioNTech €375million for its COVID-19 vaccine program at a time when Pfizer funded its development costs without government funding. In November 2020 Pfizer entered into an agreement with the European Commission and European Investment Bank, with the agreement finalized in June 2020. Pfizer has advanced purchase agreements of about US$3billion for providing a licensed vaccine in the United States, European Union, United Kingdom, Japan, Canada, Peru, and Mexico. The Initial Pivotal Phase II III Trial with the lead vaccine candidate ‘BNT162b2’ began in July.
The Phase III results indicating a 95% effectiveness of the developed vaccine were published on 18 November 2020. The vaccine was under evaluation for emergency use authorization for widespread use by several medical regulators globally. Emergency authorization is required as its Phase III clinical trials are still ongoing: monitoring of the primary outcomes will continue until August 2021, while Monitoring of the secondary outcomes will continued until January 2023. Phase I II Trials were started in Germany on 23 April 2020, and in the U.S. on 4 May 2020, with four vaccine candidates entering clinical testing. In September the Germangovernment grantedBioNTech €375m for its vaccine development and marketing rights in China, Hong Kong, Macau, and Macau. In October 2020, Pfizer received a US$135 million investment from Fosun in exchange for 1. 58 million shares in BioNTtech and the future marketing rights of BNT 162b2 in China and the other Asian countries. In June 2020, Pfizer announced that it did not want to take funding from the US government’s Operation Warp Speed for the development of the vaccine because it wanted to liberate scientists from having to give reports and agree how to spend the money in parallel. In August 2020, it was announced that Pfizer would enter into an agreement with the US Government’s Operation warp speed for the vaccine development.